Table 2 Analysis of risk factors for distant metastasis-free survival (DMFS)

SOST × menopause status

2.59 (1.80–3.73)

 < 0.001

2.12 (1.46–3.08)

 < 0.001

T stage

0.660

0.917

 T2 vs. T1

1.02 (0.71–1.46)

0.926

1.00 (0.68–1.47)

0.988

 T3 vs. T1

1.44 (0.65–3.21)

0.374

1.19 (0.51–2.79)

0.696

N stage

4.38 (3.16–6.06)

 < 0.001

4.15 (2.94–5.88)

 < 0.001

ER × PR

0.60 (0.43–0.83)

0.002

0.54 (0.35–0.82)

0.004

HER2

0.99 (0.72–1.38)

0.969

0.66 (0.38–1.16)

0.150

Ki67

0.98 (0.71–1.34)

0.877

0.98 (0.69–1.39

0.895

Molecular type

0.910

0.331

 HR + HER2 + 

 vs. HR + HER2-

0.90 (0.59–1.38)

0.645

0.68 (0.43–1.08)

0.103

 HR-HER2 + 

 vs. HR + HER2-

1.09 (0.70–1.69)

0.706

0.66 (0.38–1.16)

0.150

 TNBC

 vs. HR + HER2-

0.96 (0.60–1.56)

0.879

0.82 (0.45–1.48)

0.503